New pill tested for tough blood cancers after other treatments fail
NCT ID NCT04139434
Summary
This early-stage study tested a new oral drug called LP-108, given alone or with another cancer drug (azacitidine), in adults with advanced blood cancers that had returned or did not respond to prior treatments. The main goals were to find a safe dose, see how the body processes the drug, and check for early signs that it might help control the cancer. It involved a small group of 32 participants with specific types of leukemia and related disorders.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital San Pedro de Alcántara
Cáceres, Cáceres, 10003, Spain
-
Institut Català d'oncologia - ICO Badalona
Badalona, Barcelona, 08916, Spain
-
Instituto de Investigación Sanitaria La Fe
Valencia, Valencia, CP 46026, Spain
-
MD Anderson Cancer Center
Huston, Texas, 77030, United States
-
Ohio State Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of Cincinnati
Cincinnati, Ohio, 45221, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.